Optimal Management of Prostate Cancer Based on its Natural Clinical History
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Current cancer drug targets - 17(2017), 999, Seite 1-1 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Facchini, Gaetano [VerfasserIn] |
---|
Links: |
---|
doi: |
10.2174/1568009617666170209093101 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1993572082 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1993572082 | ||
003 | DE-627 | ||
005 | 20230513222857.0 | ||
007 | tu | ||
008 | 170512s2017 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.2174/1568009617666170209093101 |2 doi | |
028 | 5 | 2 | |a PQ20170721 |
035 | |a (DE-627)OLC1993572082 | ||
035 | |a (DE-599)GBVOLC1993572082 | ||
035 | |a (PRQ)crossref_primary_10_2174_15680096176661702090931010 | ||
035 | |a (KEY)0446469920170000017099900001optimalmanagementofprostatecancerbasedonitsnatural | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DE-600 |
084 | |a PHARM |2 fid | ||
100 | 1 | |a Facchini, Gaetano |e verfasserin |4 aut | |
245 | 1 | 0 | |a Optimal Management of Prostate Cancer Based on its Natural Clinical History |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
700 | 1 | |a Perri, Francesco |4 oth | |
700 | 1 | |a Misso, Gabriella |4 oth | |
700 | 1 | |a D`Aniello, Carmine |4 oth | |
700 | 1 | |a Scarpati, Giuseppina |4 oth | |
700 | 1 | |a Rossetti, Sabrina |4 oth | |
700 | 1 | |a Pepa, Chiara |4 oth | |
700 | 1 | |a Pisconti, Salvatore |4 oth | |
700 | 1 | |a Unteregger, Gerhard |4 oth | |
700 | 1 | |a Cossu, Alessia |4 oth | |
700 | 1 | |a Caraglia, Michele |4 oth | |
700 | 1 | |a Berretta, Massimiliano |4 oth | |
700 | 1 | |a Cavaliere, Carla |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 999, Seite 1-1 |w (DE-627)338770291 |w (DE-600)2064824-8 |w (DE-576)435515152 |x 1568-0096 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2017 |g number:999 |g pages:1-1 |
856 | 4 | 1 | |u http://dx.doi.org/10.2174/1568009617666170209093101 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_4219 | ||
951 | |a AR | ||
952 | |d 17 |j 2017 |e 999 |h 1-1 |